Significant link between sCD30 changes and HIV viremia in patients treated with HAART
(c) 2006 Wiley-Liss, Inc..
Elevated sCD30 levels were generally associated with poor prognosis in chronic HIV infection prior to the era of highly active antiretroviral therapy (HAART). Little information is available on sCD30 and HIV-1 viremia. In this study, the association between sCD30 and HIV-1 viremia was investigated in HIV-infected patients who underwent HAART. sCD30 was measured in 276 patients prior (T0) and 6 months after HAART (T6). Standard survival analyses were used to evaluate the prognostic value of sCD30 and sCD30 change from baseline to predict the virological response to HAART. Higher levels (>30 U/ml) of sCD30 prior to HAART were associated with relatively higher viremia (P = 0.0001) and tended to be associated with a lower chance of achieving virological success (P = 0.13). The median T6 sCD30 level in patients who concomitantly had viremia >500 copies/ml was higher than the median sCD30 level of those with viremia </=500 copies/ml (P = 0.002). Conversely, within the patients who achieved viral suppression on HAART, those who had concomitantly a larger reduction in sCD30 subsequently experienced a higher rate of virological failure (P = 0.04). A strong, but complex, link exists between sCD30 levels and HIV viremia in the era of HAART. The change in sCD30 levels from pre-therapy to the date of first viral suppression could be used to identify patients who are more likely to experience later virological rebound among those who achieve initially virological success.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2006 |
|---|---|
| Erschienen: |
2006 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Journal of medical virology - 78(2006), 12 vom: 01. Dez., Seite 1513-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Biswas, Priscilla [VerfasserIn] |
|---|
| Themen: |
Clinical Trial |
|---|
| Anmerkungen: |
Date Completed 09.01.2007 Date Revised 16.11.2017 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM166198579 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM166198579 | ||
| 003 | DE-627 | ||
| 005 | 20231223110312.0 | ||
| 007 | tu | ||
| 008 | 231223s2006 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0554.xml |
| 035 | |a (DE-627)NLM166198579 | ||
| 035 | |a (NLM)17063513 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Biswas, Priscilla |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Significant link between sCD30 changes and HIV viremia in patients treated with HAART |
| 264 | 1 | |c 2006 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 09.01.2007 | ||
| 500 | |a Date Revised 16.11.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a (c) 2006 Wiley-Liss, Inc. | ||
| 520 | |a Elevated sCD30 levels were generally associated with poor prognosis in chronic HIV infection prior to the era of highly active antiretroviral therapy (HAART). Little information is available on sCD30 and HIV-1 viremia. In this study, the association between sCD30 and HIV-1 viremia was investigated in HIV-infected patients who underwent HAART. sCD30 was measured in 276 patients prior (T0) and 6 months after HAART (T6). Standard survival analyses were used to evaluate the prognostic value of sCD30 and sCD30 change from baseline to predict the virological response to HAART. Higher levels (>30 U/ml) of sCD30 prior to HAART were associated with relatively higher viremia (P = 0.0001) and tended to be associated with a lower chance of achieving virological success (P = 0.13). The median T6 sCD30 level in patients who concomitantly had viremia >500 copies/ml was higher than the median sCD30 level of those with viremia </=500 copies/ml (P = 0.002). Conversely, within the patients who achieved viral suppression on HAART, those who had concomitantly a larger reduction in sCD30 subsequently experienced a higher rate of virological failure (P = 0.04). A strong, but complex, link exists between sCD30 levels and HIV viremia in the era of HAART. The change in sCD30 levels from pre-therapy to the date of first viral suppression could be used to identify patients who are more likely to experience later virological rebound among those who achieve initially virological success | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Ki-1 Antigen |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 700 | 1 | |a Cozzi-Lepri, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Delfanti, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Colangeli, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Moioli, Maria Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Scarchilli, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Abrescia, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Vigevani, Gianmarco |e verfasserin |4 aut | |
| 700 | 1 | |a D'Arminio-Monforte, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Novati, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Lazzarin, Adriano |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 78(2006), 12 vom: 01. Dez., Seite 1513-9 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2006 |g number:12 |g day:01 |g month:12 |g pages:1513-9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2006 |e 12 |b 01 |c 12 |h 1513-9 | ||